MGD019 DART(R) Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of MGD019.
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART(R) Protein Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms
- ClinicalTrials.gov Identifier: NCT03761017
- Protocol Number: 19-090
- Principal Investigator: Glen Weiss
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required